No Skin Off Your Nose: New Way to Diagnosing Parkinson’s?
Two papers report that skin samples from people with Parkinson’s disease contain α-synuclein seeds that can be robustly amplified, paving the way for a reliable test for the disease.
ALL NEWS
205 RESULTS
Sort By:
Curbing Fatty Acids Means No Parkinson’s—If You Are a Mouse
Reducing levels of monounsaturated fatty acids lowered α-synuclein toxicity and prevented movement symptoms in mice. Scientists say the data boost the α-synuclein tetramer hypothesis.
Micro Nudge? Positive Phase 2 Results for ALS Combination Drug
AMX0035, a mix of sodium phenylbutyrate and taurursodiol, slowed functional decline over six months by about as much as the approved ALS drug edaravone.
Largest Alzheimer GWAS in African Americans Finds New Variants
Most pathways that emerged were common between African Americans and non-Hispanic whites, though some individual variants differed. Kidney development jumped out as a possibly unique aspect of AD in African Americans.
Better than Crystal Clear? Cryo-EM Achieves Atomic Resolution
Armed with snazzy new hardware, scientists solve protein structures to a resolution of 1.22Å. Cryo-EM now rivals X-ray crystallography.
217—The Best Phospho-Tau Marker for Alzheimer’s?
P-tau217 appears sooner than p-tau181 in the brain, and it distinguishes AD from controls and other dementias even more cleanly.
Blunt Instruments: α-Synuclein Antibodies Poorly Distinguish Forms
A survey of 16 purported conformation-specific antibodies found that most bound nearly equally well to oligomers and fibrils, and weakly to monomers.
In APP Knock-In Mice, Spatial Mapping Circuitry Crumbles
Poor coordination among grid cells in the entorhinal cortex and place cells in the hippocampus compromises navigation. Grid cells fail first.
Do Endothelial Cells Spur Capillaries to Grow in Alzheimer’s Brain?
A new single-nucleus RNA-Seq study of 3,900 endothelial cells finds a boost in angiogenesis and antigen presentation genes, drawing attention to the vascular component of AD.
Biogen Asks FDA To Approve Aducanumab
New drug application is first for Alzheimer’s disease in the U.S. since 2003, and first based on amyloid hypothesis.
Seeing into the Human Synapse: New Tools Illuminate Alzheimer’s Hot Spot
New synaptic profiling and imaging techniques are enabling scientists to zero in on synaptic proteins, including phospho-tau, that make the difference between clinical Alzheimer’s and resilience.
Alzheimer’s Gene BIN1 Promotes Synaptic Transmission
In a conditional mouse knockout, lack of neuronal BIN1 slowed excitatory signaling, leading to spatial memory problems. Could this play a role in Alzheimer’s?
Protective AD Variant Pinpoints Sweet Spot for Microglial Activation
Phospholipase C-γ2 acts downstream of TREM2 to rev up beneficial inflammation, phagocytosis, and cell survival.
Simulating Tangle Spread Along Axons, Scientists Predict Tau PET Patterns
The modeling approach reinforces the idea that tau pathology propagates through the brain’s physical architecture, including neuronal networks.
In DIAN-TU, Gantenerumab Brings Down Tau. By a Lot. Open Extension Planned
Data shown at AAT-AD/PD explain why the DIAN-TU trial missed its primary endpoint. But gantenerumab strongly reduced plaques, tau, phospho-tau, and slowed NfL. This result prompted an open-label extension, sustaining hope for efficacy.
Current Filters
- Date Range : Oct 2019 to Oct 2020 x